Nyxoah SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Liam J. Kelly
- Full Time Employees
- 154
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Rue Edouard Belin 12 Mont-Saint-Guibert WA Belgium 1435
- IPO Date
- Sep 18, 2020
- Website
- nyxoah.com
- Similar Companies
- Business
- Nyxoah SA (NYXH) is a medical technology company focused on the development and commercialization of innovative neurostimulation solutions to treat obstructive sleep apnea (OSA). The company's lead product is the Genio system, a minimally invasive, patient-centered hypoglossal nerve stimulation therapy for adult patients with moderate to severe OSA who are intolerant of, non-compliant with, or have failed continuous positive airway pressure therapy; it features a bilateral implantable neurostimulator, wireless external activation chip, and disposable patient-controlled patches. Nyxoah markets the CE-marked Genio system across Europe and select international markets, with research, development, and manufacturing primarily based in Israel; it was founded in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. In August 2025, the US Food and Drug Administration approved the Genio system for OSA treatment, supporting the company's strong US commercial launch reported in the third quarter of 2025. Nyxoah recently secured financing commitments of up to $77 million to accelerate US commercialization and expanded its presence in the Middle East through partnerships in Abu Dhabi, Dubai, and Kuwait following the region's first Genio implant.
Company News
Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom Fisher
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
Contrasting Nephros (NASDAQ:NEPH) & Nyxoah (NASDAQ:NYXH)
Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.
Nyxoah Appoints Liam Kelly as Chief Executive Officer
Nyxoah Announces Chief Financial Officer Transition
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio®
Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript
Nyxoah Q2 Earnings Call Highlights
Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026
Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day
Nyxoah SA (NYXH) Analyst/Investor Day Transcript
Nyxoah Announces Preliminary Results for the Second Quarter of 2026
Information on the total number of voting rights and shares
Publication relating to transparency notifications
Nyxoah to Host Investor Day in New York on July 8, 2026
Invitation à assister à l'assemblée générale extraordinaire des actionnaires de la Société qui se tiendra le 9 juillet 2026